FDA: Roflumilast Foam NDA Accepted for Seborrheic Dermatitis

Press/Media

Period	1 Apr 2023

Media coverage

Title	FDA: Roflumilast Foam NDA Accepted for Seborrheic Dermatitis
Media name/outlet	Drug Topics (MJH)
Country/Territory	United States
Date	1/04/23
URL	ct.moreover.com/?a=50566138923&p=1gw&v=1&x=RE9VngjDtsfsvj9_cyR_9w
Persons	Peter Lio